

## Ikris Pharma eyes US\$ 20-25 million enterprise over the next 3 years

*Our Bureau, Mumbai, Wednesday, December 29, 2021, 11:00 Hrs [IST]*

Ikris Pharma Network, a global pharmaceutical consultancy and service company, stated that it is more focused on business process excellence (BPE) with the aim of scaling up and making Ikris a US\$ 20-25 million enterprise in the next 3 years.

The company's mission is to provide patients, healthcare personnel and the pharmaceutical industry within a country an independent global network, specializing in the distribution of future products and services to satisfy unmet medical needs where current treatment is either unavailable, or patients have exhausted all other options in their own country.

The company is planning to expand global reach by networking with patients help organizations and advocacy groups, mainly to Latin America & African countries and will provide Reference Listed Drugs (RLD) to pharmaceuticals companies for developing generic substitutes for US & European markets.

Ikris has over last the few years helped in accessing medicines for a large number of rare diseases. These diseases have ranged from duchenne muscular dystrophy (DMD) to spinal muscular atrophy (SMA) to enzyme replacement therapy (ERT) to a few acute metabolic disorders particularly conditions such as hepatic porphyria and nephropathic cystinosis.

"Generic medicines are a very important component of reducing total healthcare expenditure for the patients as well as the government. Medicines account for roughly 15-20% of total healthcare expenditure. Globally, innovator medicines account for nearly 70% of total pharma business. While innovator medicines are important for new development, accessibility of affordable medicines is also important for equitable healthcare access. As such, generic medicines help in improving affordability," stated Praveen Sikri, CEO of Ikris Pharma Network.

Sikri added that the World-over (mainly Developed nations), health regulatory authorities have defined rare diseases while also spelling out in detail diagnosis & treatment opportunity, support for new drug development & treatment reimbursement policy in their documents.

The foundation of Ikris Pharma Network was laid on the idea of transforming lives in 2014 in Noida, India. It started with a unique business model dedicated to delivering hard-to-access medicines to needy patients to save their lives and improve their lives.

[\[Close\]](#)